透析患者主动脉瓣假体选择:Medicare数据综述
该研究基于2009至2019年Medicare数据,比较透析患者接受生物瓣AVR、机械瓣AVR和TAVR的结局。匹配后生物瓣与机械瓣5年生存无差异,SAVR早期生存劣于TAVR但5年生存更优。
要点
- 透析患者生物瓣与机械瓣AVR的5年生存无显著差异。
- 机械瓣胃肠道出血再入院更高,再手术率更低。
- SAVR较TAVR早期生存更差但5年生存更优。
核心结论
- 透析患者无论选择何种瓣膜,生存均较差、出血风险高、再手术率低。
- 生物瓣与机械瓣AVR的5年总体生存无差异。
- SAVR与TAVR相比,早期生存更差但5年总体生存更优。
研究设计与样本
- 基于Medicare Provider Analysis and Review数据的回顾性队列研究。
- 纳入2009至2019年接受生物瓣AVR、机械瓣AVR和TAVR的透析患者。
- 进行两组倾向性评分匹配:生物瓣AVR vs 机械瓣AVR,以及SAVR vs TAVR。
主要发现
- 机械瓣AVR组2590例,生物瓣AVR组4752例,TAVR组7739例;平均年龄分别为61.5、66.6和73.2岁。
- SAVR与TAVR组胃肠道出血再入院率(约31%)和再手术率(约3%)相似。
临床怎么用
- 透析患者选择生物瓣或机械瓣时,5年生存无差异,需权衡出血与再手术风险。
- 与TAVR相比,SAVR早期生存更差但5年生存更优,决策需结合患者预期寿命和手术风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The choice between bioprosthetic or mechanical surgical aortic valve replacement (SAVR) for dialysis patients is debated. Rapid adoption of transcatheter aortic valve replacement (TAVR) complicates decision-making further. This study compared AVR prosthesis choices among dialysis patients. METHODS: Dialysis patients who underwent bioprosthetic AVR (bAVR), mechanical AVR (mAVR), and TAVR from 2009 to 2019 were queried from Medicare Provider Analysis and Review data. Two propensity score matches were performed: bAVR vs mAVR and SAVR (bAVR + mAVR) vs TAVR. Survival at 5 years was compared using restricted mean survival time (RMST). Secondary outcomes were compared using subhazard regression with death as a competing risk. RESULTS: Among 2590 patients who underwent mAVR, 4752 underwent bAVR and 7739 underwent TAVR; mean ages were 61.5, 66.6, and 73.2 years, respectively. Matching mAVR and bAVR yielded 2460 patients each. Survival was similar, with RMST of 2.67 years for mAVR and 2.60 years for bAVR (difference = -0.07, P = .170). For mAVR, gastrointestinal bleeding readmission was higher (32.7% vs 28.6%, P = .002), whereas reoperation was lower (3.6% vs. 5.8%, P < .001). Matching SAVR and TAVR yielded 2709 patients each. SAVR had worse early but improved 5-year survival, with RMST of 2.43 vs 2.18 years (difference = -0.25, P < .001). Readmissions for gastrointestinal bleeding (∼31%) and reoperation (∼3%) were similar. CONCLUSIONS: Dialysis patients undergoing SAVR and TAVR have poor survival, high bleeding risk, and low reoperation rate regardless of prosthesis choice. Our data suggest no difference in 5-year overall survival between bAVR and mAVR, whereas SAVR was associated with worse early but improved 5-year overall survival compared with TAVR.
引用
- Lutfi W, Desai ND, Pan Z, et al. Aortic Valve Prosthesis Choice in Dialysis Patients: A Review of Medicare Data. Ann Thorac Surg. 2026. PMID: 41839431. doi:10.1016/j.athoracsur.2026.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。